Oculis to Present at H.C. Wainwright Annual Ophthalmology Conference
ZUG, Switzerland — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) is excited to announce its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. This event brings together leaders and visionaries in the ophthalmic and neuro-ophthalmic fields to discuss significant innovations and research.
Key Presentations at the Conference
Oculis’ management team will play an integral role in this conference, presenting crucial insights into the company’s developments and future plans. Sylvia Cheung, the Chief Financial Officer of Oculis, will deliver a corporate update. Attendees can look forward to the replay of her presentation available via webcast at 7:00 am ET.
Additionally, the company’s President of R&D, Snehal Shah, will engage in a live panel discussion focused on pivotal-stage assets for retinal disorders. This session will occur from 11:00 am to 12:00 pm ET and will also be accessible for replay afterwards.
Understanding Oculis: Innovation Meets Unmet Medical Needs
Oculis is a pioneering biopharmaceutical company that specializes in innovative solutions for treating ophthalmic and neuro-ophthalmic conditions. The company’s commitment to addressing various significant unmet medical needs is reflected in its highly differentiated late-stage clinical pipeline. This includes groundbreaking candidates that hold promise for transforming therapies in their respective fields.
Oculis’ Groundbreaking Projects
Among the leading candidates is OCS-01, an eye drop in pivotal registration studies designed to be the first non-invasive topical treatment for diabetic macular edema. This innovative approach aims to significantly change how medical professionals handle this condition, offering hope for many patients.
Another remarkable product in development is Privosegtor (OCS-05), which is currently undergoing Phase 2 trials as a neuroprotective candidate for treating acute optic neuritis. This therapy is anticipated to have broad applications, potentially benefiting various neuro-ophthalmic and neurological conditions.
Furthermore, Licaminlimab (OCS-02) is under Phase 2 development as a novel topical anti-TNF? treatment. This research is particularly focused on utilizing genotype-based approaches to enhance personalized medicine in managing dry eye disease (DED).
Company Commitment and Future Directions
Headquartered in Switzerland, Oculis operates across the U.S. and Iceland, led by a competent management team equipped with a successful history in the healthcare sector. Their strategic efforts are supported by prominent international healthcare investors, highlighting the confidence placed in Oculis’ vision and capabilities.
The upcoming conference represents a critical opportunity for Oculis not only to share its achievements but also to engage with experts and potential investors who share the goal of advancing ophthalmic care.
For More Information
Interested individuals can find additional details about the conference and the company’s updates by visiting Oculis' official website. For those keen on learning more about their innovations and ongoing projects in ophthalmology, visiting the company’s resources will provide a comprehensive overview.
Frequently Asked Questions
What is the purpose of Oculis’ participation in the conference?
Oculis aims to present its latest innovations, discuss pivotal products, and engage with experts in the ophthalmic field.
Who will be presenting at the conference?
Sylvia Cheung, CFO, will provide a corporate update, and Snehal Shah, President of R&D, will participate in a panel discussion.
How does Oculis address unmet medical needs?
Oculis focuses on innovative solutions tailored for ophthalmic and neuro-ophthalmic conditions, enhancing treatment options for severe medical issues.
What are the key products that Oculis is developing?
Oculis is developing important candidates like OCS-01, Privosegtor (OCS-05), and Licaminlimab (OCS-02) aimed at various eye-related conditions.
Where is Oculis headquartered?
The company is based in Switzerland but also operates in the U.S. and Iceland, highlighting its international reach in healthcare innovation.
